Is Kymera Therapeutics Inc (KYMR) a Bad Choice in Biotechnology Tuesday?

A rating of 68 puts Kymera Therapeutics Inc (KYMR) near the top of the Biotechnology industry according to InvestorsObserver. Kymera Therapeutics Inc's score of 68 means it scores higher than 68% of stocks in the industry. Kymera Therapeutics Inc also received an overall rating of 61, putting it above 61% of all stocks. Biotechnology is ranked 18 out of the 148 industries.

KYMR has an Overall Score of 61. Find out what this means to you and get the rest of the rankings on KYMR!

See Full KYMR Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 61 would rank higher than 61 percent of all stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Kymera Therapeutics Inc Stock Today?

Kymera Therapeutics Inc (KYMR) stock has fallen -1.06% while the S&P 500 is higher by 0.88% as of 10:32 AM on Tuesday, Mar 12. KYMR is down -$0.45 from the previous closing price of $42.29 on volume of 69,756 shares. Over the past year the S&P 500 has gained 33.90% while KYMR is higher by 34.06%. KYMR lost -$2.52 per share the over the last 12 months. Click Here to get the full Stock Report for Kymera Therapeutics Inc stock.